Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 741 to 750 of 1000 total matches.
Iptacopan (Fabhalta) for Paroxysmal Nocturnal Hemoglobinuria (online only)
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024 (Issue 1712)
from Central Europe on special patient populations.
Adv Ther 2023; 40:2752.
5. R Peffault de Latour et al ...
The FDA has approved the complement factor B
inhibitor iptacopan (Fabhalta – Novartis) for
treatment of paroxysmal nocturnal hemoglobinuria
(PNH) in adults. Iptacopan is the first oral drug to
be approved in the US for this indication. Three
parenterally administered drugs, the complement
C5 inhibitors eculizumab (Soliris) and ravulizumab
(Ultomiris) and the complement C3 inhibitor
pegcetacoplan (Empaveli), are also approved for
treatment of PNH.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e171-3 doi:10.58347/tml.2024.1712e | Show Introduction Hide Introduction
Xanomeline/Trospium (Cobenfy) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
. R Marcus et al. Long-term safety of KarXT (xanomeline and
trospium) in schizophrenia. Abstract F74 ...
The FDA has approved Cobenfy (BMS), an oral
fixed-dose combination of the muscarinic agonist
xanomeline and the peripheral muscarinic antagonist
trospium chloride, for treatment of schizophrenia in
adults. It is the first antipsychotic drug to be approved
in the US for treatment of schizophrenia that does not
block dopamine receptors. This is the first approval
for xanomeline; trospium has been available for many
years for treatment of overactive bladder.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):177-9 doi:10.58347/tml.2024.1715a | Show Introduction Hide Introduction
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022 (Issue 1653)
; 9:138.
12. R Selb et al. Markedly decreasing azithromycin susceptibility
of Neisseria gonorrhoeae ...
This article includes recommendations for management
of most sexually transmitted infections (STIs)
other than HIV and viral hepatitis. Some of the
indications and dosages recommended here have
not been approved by the FDA (see Table 1).
Drugs for Cognitive Loss and Dementia
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022 (Issue 1657)
disease combined
with cerebrovascular disease: a randomised trial. Lancet
2002; 359:1283.
22. R Bullock ...
Alzheimer's disease (AD) is the most common
cause of dementia, but cognitive decline is also
associated with other neurological conditions such
as Parkinson's disease, dementia with Lewy bodies,
vascular dementia, and frontotemporal dementia.
Drugs for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024 (Issue 1712)
, and an increased risk of sunburn can occur.
TAPINAROF — The aryl hydrocarbon receptor (AhR)
agonist tapinarof ...
Mild to moderate plaque psoriasis can be treated
with topical drugs and phototherapy. Patients
with moderate to severe disease generally require
systemic therapy. Guidelines for the treatment of
psoriasis with topical therapy, phototherapy, and
systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60 doi:10.58347/tml.2024.1712a | Show Introduction Hide Introduction
Drugs for HIV Infection
Treatment Guidelines from The Medical Letter • Feb 01, 2014 (Issue 138)
Bánhegyi et al. Week 96 efficacy, virology and safety of darunavir/r
versus lopinavir/r in treatment ...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.
Interferon Treatment of Genital Warts
The Medical Letter on Drugs and Therapeutics • Jul 15, 1988 (Issue 770)
requiring weeks for healing (A Ferenczy, Obstet Gynecol, 64:773, 1984; R Reid, Am J
Obstet Gynecol, 151 ...
Recombinant interferon alfa-2b (Intron A - Schering) was recently approved by the US Food and Drug Administration (FDA) for intralesional treatment of genital warts (condylomata acuminata). Interferon was previously available only for treatment of hairy-cell leukemia (Medical Letter, 28:78, 1986).
Drugs for Hypertensive Emergencies
The Medical Letter on Drugs and Therapeutics • Apr 07, 1989 (Issue 789)
plasma volumes and renin activities, the response to enalaprilat is unpredictable and variable (R ...
Hypertensive emergencies include hypertensive encephalopathy, intracranial hemorrhage with hypertension, aortic dissection, acute pulmonary edema with hypertension, acute cardiac ischemia with hypertension, malignant hypertension and severe hypertension after vascular surgery; hypertensive crisis due to pheochromocytoma or occurring during pregnancy is not discussed in this review. Although immediate reduction of blood pressure is necessary in hypertensive emergencies, an excessive decrease may cause stroke, myocardial infarction or visual changes. Most experienced clinicians aim...
Use of Nicotine to Stop Smoking
The Medical Letter on Drugs and Therapeutics • Jan 20, 1995 (Issue 940)
anxiety problems (R West et al, Psychopharmacology, 104:91, 1991). Various antidepressants have also ...
Many patients ask physicians to help them stop smoking. Since nicotine gum and patches were first marketed (Medical Letter, 26:47, 1984; 34:37, 1992), more data have become available on their effective use, and new formulations of the drug have been developed. Because of its slower rate of absorption, nicotine from gum or patches does not produce the pleasure some people associate with cigarette smoking, but it can relieve the irritability, difficulty in concentrating and other symptoms that occur after withdrawal from smoking.
Two New Drugs for Epilepsy
The Medical Letter on Drugs and Therapeutics • Apr 17, 2000 (Issue 1076)
Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt
School of Medicine; F. Estelle R. Simons, M.D ...
Oxcarbazepine, which is chemically similar to carbamazepine, and levetiracetam, a pyrrolidine acetamide chemically unrelated to other antiepileptic drugs, are the sixth and seventh drugs approved by the US Food and Drug Administration in the last five years for oral use in partial seizures.